CPPD-differential diagnostics and differential therapeutic challenges

Abstract

Calcium pyrophosphate deposition disease (CPPD), characterized by the presence of calcium pyrophosphate crystals in and around joints, poses diagnostic and therapeutic challenges in rheumatology. This review provides a comprehensive overview of CPPD, focusing on its diagnosis, differential diagnosis, therapeutic challenges, and monitoring, with insights into the association between CPPD and cardiovascular risk. Diagnostics in CPPD rely on identifying CPP crystals in synovial fluid or joint tissues, with imaging modalities such as ultrasound and conventional radiography emerging as valuable tools. The 2023 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria prioritize imaging evidence of CPP crystal deposition and recurrent episodes of acute inflammatory arthritis, aiding in standardized diagnosis. Differential diagnosis includes distinguishing CPPD from gout, osteoarthritis, rheumatoid arthritis, basic calcium phosphate deposition disease, and other inflammatory arthropathies. Therapeutic challenges in CPPD management revolve around symptomatic relief, with no targeted therapy to influence CPP deposition currently available. Management strategies include symptom-directed treatments like NSAIDs, steroids and colchicine. IL-6 inhibition with tocilizumab shows promise for refractory cases. Monitoring CPPD involves assessing joint symptoms, inflammation, and cardiovascular risk factors, with regular clinical evaluation. In conclusion, CPPD presents a complex challenge in rheumatology, requiring a nuanced approach to diagnosis and management. Ongoing research is needed to deepen our understanding of CPPD mechanisms and explore novel therapeutic avenues.

Keywords

CPPD / calcium pyrophosphate crystal deposition / chondrocalcinosis

References

[1] Doherty M, Dieppe PA. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee. Lancet. 1981; 2: 1243-6.

[2] Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000; 289: 265-70.

[3] Netter P, Bardin T, Bianchi A, Richette P, Loeuille D. The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease. Joint Bone Spine. 2004; 71: 365-8.

[4] Chang CC, Lee KL, Chan TS, Chung CC, Liang YC. Histone Deacetylase Inhibitors Downregulate Calcium Pyrophosphate Crystal Formation in Human Articular Chondrocytes. Int J Mol Sci. 2022; 23: 2604.

[5] Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237-41.

[6] Cheung HS, Halverson PB, McCarty DJ. Release of collagenase, neutral protease, and prostaglandins from cultured mammalian synovial cells by hydroxyapatite and calcium pyrophosphate dihydrate crystals. Arthritis Rheum. 1981; 24: 1338-44.

[7] Richette P, Ayoub G, Lahalle S, Vicaut E, Badran AM, Joly F, et al. Hypomagnesemia associated with chondrocalcinosis: a cross-sectional study. Arthritis Rheum. 2007; 57: 1496-501.

[8] Chuck AJ, Pattrick MG, Hamilton E, Wilson R, Doherty M. Crystal deposition in hypophosphatasia: a reappraisal. Ann Rheum Dis. 1989; 48: 571-6.

[9] de Lange EE, Keats TE. Localized chondrocalcinosis in traumatized joints. Skeletal Radiol. 1985; 14: 249-56.

[10] Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011; 70: 563-70.

[11] McCarty DJ. Calcium pyrophosphate dihydrate crystal deposition disease--1975. Arthritis Rheum. 1976; 19: 275-85.

[12] Sissons HA, Steiner GC, Bonar F, May M, Rosenberg ZS, Samuels H, et al. Tumoral calcium pyrophosphate deposition disease. Skeletal Radiol. 1989; 18: 79-87.

[13] Ishida T, Dorfman HD, Bullough PG. Tophaceous pseudogout (tumoral calcium pyrophosphate dihydrate crystal deposition disease). Hum Pathol. 1995; 26: 587-93.

[14] Abhishek A, Tedeschi SK, Pascart T, Latourte A, Dalbeth N, Neogi T, et al. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Ann Rheum Dis. 2023; 82: 1248-57.

[15] Oliviero F, Scanu A, Galozzi P, Gava A, Frallonardo P, Ramonda R, et al. Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine. 2013; 80: 287-90.

[16] Altomare A, Corrado A, Maruotti N, Cici D, Cantatore FP. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease. Mol Biol Rep. 2021; 48: 4789-96.

[17] Fuller A, Cai K, Filippou G, Pascart T, Diaz-Torne C, Hensey O, et al. Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group. Semin Arthritis Rheum. 2021; 51: 655-60.

[18] Ivorra J, Rosas J, Pascual E. Most calcium pyrophosphate crystals appear as non-birefringent. Ann Rheum Dis. 1999; 58: 582-4.

[19] Martínez Sanchis A, Pascual E. Intracellular and extracellular CPPD crystals are a regular feature in synovial fluid from uninflamed joints of patients with CPPD related arthropathy. Ann Rheum Dis. 2005; 64: 1769-72.

[20] Utsinger PD. Synovial fluid lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1975; 18: 595-602.

[21] Adinolfi A, Sirotti S, Sakellariou G, Cipolletta E, Filippucci E, Porta F, et al. Which are the most frequently involved peripheral joints in calcium pyrophosphate crystal deposition at imaging? A systematic literature review and meta-analysis by the OMERACT ultrasound - CPPD subgroup. Front Med (Lausanne). 2023; 10: 1131362.

[22] Frediani B, Filippou G, Falsetti P, Lorenzini S, Baldi F, Acciai C, et al. Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed. Ann Rheum Dis. 2005; 64: 638-40.

[23] Filippou G, Frediani B, Gallo A, Menza L, Falsetti P, Baldi F, et al. A “new” technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography. Ann Rheum Dis. 2007; 66: 1126-8.

[24] Barskova VG, Kudaeva FM, Bozhieva LA, Smirnov AV, Volkov AV, Nasonov EL. Comparison of three imaging techniques in diagnosis of chondrocalcinosis of the knees in calcium pyrophosphate deposition disease. Rheumatology (Oxford). 2013; 52: 1090-4.

[25] Cipolletta E, Moscioni E, Sirotti S, Di Battista J, Abhishek A, Rozza D, et al. Diagnosis of calcium pyrophosphate crystal deposition disease by ultrasonography: how many and which sites should be scanned? Rheumatology (Oxford). 2024; 63: 2205-12.

[26] Sirotti S, Terslev L, Filippucci E, Iagnocco A, Moller I, Naredo E, et al.; OMERACT Ultrasound working group-CPPD subgroup. Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level. Lancet Rheumatol. 2023; 5: e474-82.

[27] Cipolletta E, Di Matteo A, Smerilli G, Di Carlo M, Di Battista J, Abhishek A, et al. Ultrasound findings of calcium pyrophosphate deposition disease at metacarpophalangeal joints. Rheumatology (Oxford). 2022; 61: 3997-4005.

[28] Becce F. Diagnosis of calcium pyrophosphate deposition by imaging - current state and challenges remaining. Osteoarthritis Cartilage. 2019; 27: 545-6.

[29] Tedeschi SK, Solomon DH, Yoshida K, Vanni K, Suh DH, Smith SE. A prospective study of dual-energy CT scanning, US and X-ray in acute calcium pyrophosphate crystal arthritis. Rheumatology (Oxford). 2020; 59: 900-3.

[30] Budzik JF, Marzin C, Legrand J, Norberciak L, Becce F, Pascart T. Can Dual-Energy Computed Tomography Be Used to Identify Early Calcium Crystal Deposition in the Knees of Patients With Calcium Pyrophosphate Deposition? Arthritis Rheumatol. 2021; 73: 687-92.

[31] Dirim B, Resnick D, Abreu M, Wangwinyuvirat M, Trudell DJ, Haghighi P. Relationship between the degeneration of the cruciate ligaments and calcium pyrophosphate dihydrate crystal deposition: anatomic, radiologic study with histologic correlation. Clin Imaging. 2013; 37: 342-7.

[32] Abreu M, Johnson K, Chung CB, De Lima JE Jr, Trudell D, Terkeltaub R, et al. Calcification in calcium pyrophosphate dihydrate (CPPD) crystalline deposits in the knee: anatomic, radiographic, MR imaging, and histologic study in cadavers. Skeletal Radiol. 2004; 33: 392-8.

[33] Filippou G, Scanu A, Adinolfi A, Picerno V, Toscano C, Bortoluzzi A, et al. The two faces of the same medal… or maybe not? Comparing osteoarthritis and calcium pyrophosphate deposition disease: a laboratory and ultrasonographic study. Clin Exp Rheumatol. 2021; 39: 66-72.

[34] Krekeler M, Baraliakos X, Tsiami S, Braun J. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022; 8: e002383.

[35] Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011; 70: 571-5.

[36] Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed. 1996; 63: 248-54.

[37] Roane DW, Harris MD, Carpenter MT, Finger DR, Jarek MJ, Alloway JA, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997; 24: 1168-70.

[38] Pascart T, Robinet P, Ottaviani S, Leroy R, Segaud N, Pacaud A, et al. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. Lancet Rheumatol. 2023; 5: e523-31.

[39] Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994; 21: 696-9.

[40] Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997; 23: 327-31.

[41] Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007; 56: 688-92.

[42] Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986; 13: 804-5.

[43] Announ N, Palmer G, Guerne PA, Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009; 76: 424-6.

[44] Moltó A, Ea HK, Richette P, Bardin T, Lioté F. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012; 79: 621-3.

[45] Dumusc A, Pazar Maldonado B, Benaim C, Zufferey P, Aubry-Rozier B, So A. Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study. Joint Bone Spine. 2021; 88: 105088.

[46] Desmarais J, Chu CQ. Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center. J Rheumatol. 2019; 46: 748-50.

[47] Lian A, Shandilya A, Riordan J. A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease. Clin Rheumatol. 2023; 42: 1833-7.

[48] So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010; 62: 3064-76.

[49] Klück V, Jansen TLTA, Janssen M, Comarniceanu A, Efdé M, Tengesdal IW, et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020; 2: e270-80.

[50] Finckh A, Mc Carthy GM, Madigan A, Van Linthoudt D, Weber M, Neto D, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014; 16: 458.

[51] Latourte A, Ea HK, Frazier A, Blanchard A, Lioté F, Marotte H, et al. Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study. Ann Rheum Dis. 2020; 79: 1126-8.

[52] Runeberg L, Collan Y, Jokinen EJ, Lähdevirta J, Aro A. Hypomagnesemia due to renal disease of unknown etiology. Am J Med. 1975; 59: 873-81.

[53] Rosenthal AK, Ryan LM. Probenecid inhibits transforming growth factor-beta 1 induced pyrophosphate elaboration by chondrocytes. J Rheumatol. 1994; 21: 896-900.

[54] Tedeschi SK, Huang W, Yoshida K, Solomon DH. Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis. Ann Rheum Dis. 2022; 81: 1323-9.

[55] Lioté F. Treatment of hyperuricemia, gout and other crystalline arthritidies. Reumatismo. 2012; 63: 276-83.

[56] Gwinnutt JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, Boonen A, Cavalli G, et al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023; 82: 48-56.